Lexicon licenses sotagliflozin ex-US/Europe to Viatris for $25M upfront plus milestones

LEXICON PHARMACEUTICALS, INC.

Exclusive license to Viatris for sotagliflozin development and commercialization outside US and Europe.
Viatris pays $25M upfront; Lexicon eligible for up to $12M regulatory and $185M sales milestones.
Tiered royalties: low double-digit to upper-teens percentages of net sales in licensed territory.
Lexicon to supply drug under a separate manufacturing and supply agreement with Viatris.
Viatris responsible for regulatory approvals, commercialization, and any additional clinical trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.